In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies

Chemotherapy

Volumn 53, Issue 3, 2007, Pages 194-201

  Isla, Arantxazu ^a   Gascón, Alicia R ^a   Maynar, Javier ^b   Arzuaga, Alazne ^a   Sánchez Izquierdo, José Antonio ^c   Pedraz, José Luis ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Ceftazidime; Continuous renal replacement therapies

Indexed keywords

CEFTAZIDIME; POLYSULFONE; RINGER LACTATE SOLUTION;

ABSENCE OF SIDE EFFECTS; ADULT; ANURIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CASE REPORT; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE; MEMBRANE PERMEABILITY; NEPHROTOXICITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ACRYLIC RESINS; ACRYLONITRILE; ADULT; ALBUMINS; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; ISOTONIC SOLUTIONS; KIDNEY DISEASES; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PERMEABILITY; PLASMA; POLYMERS; SULFONES;

EID: 34147196078     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100864     Document Type: Article

References (41)

1. Rains CP, Bryson HM, Peters DH: Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995;49:577-617.
2. Tumanh H: Fourth-generation cephalosporins: in vitro activity against nosocomial gram-positive bacilli compared with beta-lactam antibiotics and ciprofloxacin. Chemotherapy 2005;51:80-85.
3. Traunmüller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F: Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002;49:129-134.
4. Gómez CMH, Cordingly JJ, Palazzo MGA: Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999;43:1798-1802.
5. Naber KG, Kees F, Grobecker H: Ceftazidime; pharmacokinetics in young volunteers versus elderly patients and therapeutics efficacy with complicated urinary tract infections. J Antimicrob Chemother 1984;25:201-204.
6. Kuti JL, Nicolau DP: Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy 2005;51:211-216.
7. Isla A, Maynar J, Sánchez-Izquierdo JA, Gascón AR, Arzuaga A, Corral E, Pedraz JL: Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol 2005;45:1294-1304.
8. Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL: Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther 2005;27:599-608.
9. Malone RS, Fish DN, Abraham E, Teitelbaum I: Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001;45:3148-3155.
10. Arzuaga A, Maynar J, Gascon AR, Isla A, Corral E, Fonseca F, Sanchez-Izquierdo JA, Rello J, Canut A, Pedraz JL: Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005;45:168-176.
11. Matzke GR, Frye RF, Joy MS, Palevsky PM: Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000;44:1639-1644.
12. Banner W, Swenson E, Vernon DD, Dean JM, Gooch WM: Ceftazidime dosing in continuous arteriovenous hemofiltration. Clin Pharm 1989;8:91.
13. Vos MC, Vincent HH, Yzerman EPF, Vogel M, Mouton JW: Drug clearance by continuous haemofiltration. Results with the AN-69 capillary haemofilter and recommended dose adjustments for seven antibiotics. Drug Invest 1994;7:315-322.
14. Sato T, Okamoto K, Kitaura M, Kukita I, Kikuta K, Hamaguchi M: The pharmacokinetics of ceftazidime during hemofiltration in critically ill patients. Artif Organs 1999;23:143-145.
15. Davies SP, Lacey LF, Kox WJ, Brown EA: Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis. Nephrol Dial Transplant 1991;6:971-976.
16. Malone RS, Fish DN, Abraham E, Teitelbaum I: Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001;45:3148-3155.
17. Isla A, Arzuaga A, Maynar J, Gascon AR, Solinis MA, Corral E, Pedraz JL: Determination of ceftazidime and cefeprime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC. J Pharm Biomed Anal 2005;39:996-1005.
18. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al: Bioanalytical method validation. A revisit with a decade of progress. Workshop/Conference Report. Pharm Res 2000;17:1551-1557.
19. Food and Drug Administration: Guidance for Industry: Bioanalytical Methods Validation for Human Studies. Rockville, Center for Drug Evaluation and Research, 1998.
20. Golper TA, Wedel SK, Kaplan AA, Saad AM, Donta ST, Paganini EP: Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 1985;8:307-312.
21. Bauer LA, Gibaldi M: Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci 1983;72:978-979.
22. Lee CS, Marbury TC: Drug therapy in patients undergoing hemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet 1984;9:42-66.
23. Kroh UF: Drug administration in critically ill patients with acute renal failure. New Horizons 1995;3:748-759.
24. Krueguer WA, Schroeder TH, Hutchison M, Hoffmann E, Dieterich HJ, Heininger A, Erley C, Wehrle A, Unertl K: Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998;42:2421-2424.
25. Golper TA: Drug removal during continuous hemofiltration or hemodialysis. Contrib Nephrol 1991;93:110-116.
26. Relton S, Greenberg A, Palevsky PM: Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. ASAIO J 1992;38:M691-M696.
27. Zarowitz BJ, Anandan JV, Dumler F, Jayashankar J, Levin N: Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol 1986;26:686-689.
28. Lau AH, Kronfol NO: Elimination of flucytosine by continuous hemofiltration. Am J Nephrol 1995;15:327-331.
29. Ernest D, Cutler DJ: Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med 1992;20:586-589.
30. Joy MS, Matzke GR, Frye RF, Palevsky PM: Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 1998;31:1019-1027.
31. Matzke GR, Frye RF, Joy MS, Palevsky PM: Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy 2000;20:635-643.
32. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA: Intermittent and continuous infusion for critically ill trauma patients. Am J Surg 2000;179:436-440.
33. Reed RL, Ericsson CD, Wu A, Miller-Crotchett P, Fischer RP: The pharmacokinetics of prophylactic antibiotic in trauma. J Trauma 1992;32:21-27.
34. Townsend PL, Fink MP, Stein KL, Murphy SG: Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med 1989;17:154-157.
35. Botha FJ, van der Bijl P, Seifart HI, Parkin DP: Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 1996;22:433-436.
36. Fernández de Gatta MM, Mendez ME, Romano S, Calvo MV, Domínguez-Gil A, Lanao JM: Pharmacokinetics of amikacin in intensive care patients. J Clin Pharm Ther 1996;21:417-421.
37. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ: The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995;28:143-160.
38. Craig WA: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
39. Craig WA, Ebert SC: Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-2583.
40. Valtonen M, Tiula E, Backman JT, Neuvonen PT: Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000;45:701-704.
41. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale antibacterial dosing in mice and men. Clin Infect Dis 1998;26:1-12.